IGF-1 LR3

IGF-1 LR3 is a recombinant research analog of insulin-like growth factor-1. The Long Arg3 design combines an N-terminal extension with an arginine substitution at position 3, which reduces binding to IGF-binding proteins in the systems where that property was originally characterised.

For a purchasing laboratory the practical identity question is the analog designation on the certificate — LongR3 versus native IGF-1 versus truncated Des(1-3) forms — because those species are analytically distinct.

VaultLabs catalogs a 100 mcg lyophilised presentation for in vitro workflows. That fill mass is typical of growth-factor reference use rather than bulk reagent supply.

Foundational characterisation of Long Arg3 fusion analogs comes from early-1990s recombinant IGF research describing potency relative to native IGF-1 in cell systems that secrete IGF-binding proteins.

A later analytical strand addresses detection of LongR3 and related analogs in anti-doping and forensic contexts, which is a legitimate laboratory use case for characterised reference material.

VaultLabs makes no claims about physiological or clinical effects and does not supply this material for human use.

Release is by HPLC against a stated purity specification with a lot-linked certificate. Growth-factor analogs benefit from mass confirmation where instrumentation allows, because truncated or oxidised forms can co-elute under non-optimised methods.

Store sealed lyophilised vials at 2–8 °C, protected from light and humidity, and equilibrate to room temperature before opening. Reconstitute gently and minimise freeze-thaw cycles.

IGF-1 LR3 is not an approved medicine and is not supplied for human or veterinary use.

VaultLabs IGF-1 LR3 is a research reference material for in vitro laboratory use only. Orders are accepted against a research-use declaration retained in the order record.

The catalog presentation is a 100 mcg lyophilised vial with lot-linked certificate retrieval through batch verification when published.

Laboratories comparing IGF analogs should treat LongR3, R3 and Des(1-3) forms as distinct analytical targets rather than interchangeable stock codes. Incoming-goods checks that confirm mass and chromatographic identity reduce the risk of mixing those forms in a shared freezer inventory.

UAE dispatch uses temperature-aware packaging where configured; the transfer from courier to laboratory cold storage remains the weakest point in Gulf summer conditions and is worth documenting as a receipt step. VaultLabs does not provide reconstitution recipes for human use and will not advise on administration under any circumstance.

Procurement records should retain the lot number, certificate reference and research-use declaration. Those artefacts are what an institutional audit will ask for if the material later appears in a methods appendix or materials list.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature.

IGF receptor binding assays

IGF-binding protein interaction studies

Cell-culture growth-factor panels

Analytical method development for IGF analogs

2–8 °C (lyophilized, sealed)

2–8 °C sealed lyophilized storage; protect from light and moisture.

Growth-factor analogs require sealed cold storage and careful reconstitution to avoid aggregation. Verify integrity via COA HPLC before incorporation into long-running assays.